Alzheimer's Doctors On Biogen's New Drug; Tax Inequality : Here & Now There's excitement — and controversy — surrounding Biogen's new Alzheimer's drug. What are doctors saying? Dr. Jason Karlawish and Dr. Gayatri Devi discuss the drug's promise and peril. And, ProPublica revealed a trove of tax records showing the megarich pay next to nothing in income taxes. Robert McClelland of the Urban-Brookings Tax Policy Center weighs in.

Alzheimer's Doctors On Biogen's New Drug; Tax Inequality

Alzheimer's Doctors On Biogen's New Drug; Tax Inequality

  • Download
  • <iframe src="https://www.npr.org/player/embed/1005207007/1005235325" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

There's excitement — and controversy — surrounding Biogen's new Alzheimer's drug. What are doctors saying? Dr. Jason Karlawish and Dr. Gayatri Devi discuss the drug's promise and peril. And, ProPublica revealed a trove of tax records showing the megarich pay next to nothing in income taxes. Robert McClelland of the Urban-Brookings Tax Policy Center weighs in.

Connect with us:

Find more stories from the show here.

Follow us on Twitter, Facebook and Instagram.

Subscribe to our podcast here.

Email the show at letters@hereandnow.org